期刊文献+

肥胖症治疗药物的不良反应 被引量:6

Adverse reactions of anti-obesity agents
下载PDF
导出
摘要 肥胖是多种因素共同作用的结果,目前真正被批准可以被长期用于减重的药物主要分为两类:一类是作用于中枢神经系统的食欲抑制剂;另一类是抑制肠道吸收脂肪的药物。在肥胖患病率日益增高的情况下,减肥药物的不良反应尤为关注。可以说减肥药物发展的历史就是其有效性与安全性相博弈的历程,本文就目前临床被批准可以长期使用的减肥药物的心血管系统不良反应、消化系统不良反应、肝脏不良反应、致畸作用等常见不良反应进行简要综述,来指导临床上肥胖治疗药物的合理选择。
作者 刘超 狄红杰
出处 《药品评价》 CAS 2013年第9期36-40,共5页 Drug Evaluation
  • 相关文献

参考文献15

  • 1Dang MN, Hashem BE. The epidemiology of obesity[J]. Gastroenterol Clin Nor Amer, 2010, 39(1): 1-7.
  • 2Surapaneni P, Vinales K L, NajibMohammad Q, et al. Valvular heart disease with the use of fenfluramine-phentermine[J]. Tex Heart Instit J, 2011, 38(5): 581-583.
  • 3Weeke P, Andersson C, Fosbl EL, et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period[J]. BMC Endocr Dis, 2010, 10: 3.
  • 4Philip J, lan C, Walmir C, et al. Effect on mortality and morbidity in overweight/obese subjects: the sibutramine cardiovascular outcomes(SCOUT) trial[J]. J Amer College Cardiol, 2010, 55(10): A141.
  • 5Hurren KM, Berlie HD. Lorcaserin. An investigational serotonin 2C agonist for weight loss[J]. Am J Health Syst Phann, 2011,68(21): 2029-2037.
  • 6Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women[J]. Obesity, 2009, 17: 494-503.
  • 7Smith SR, Weissman N J, Anderson CM, et al. Multicenter, placebo- controlled trial of lorcaserin for weight management[J]. N Engl J Med, 2010, 363: 245-256.
  • 8Patrick MN, Steven RS, Neil JW, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM Study[J]. Obesity, 2012, 20(7): 1426-1436.
  • 9Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled- release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011,377: 1341-1352.
  • 10Steven MS, Melissa M, Katy ET. Phentermine/Topiramate for the treatment of obesity[J]. Ann Pharmacother, 2013, 47: 340-349.

同被引文献92

  • 1宁远.瓣膜性心脏病与芬氟拉明和芬特明的关系[J].中华医学信息导报,1998,0(1):21-21. 被引量:1
  • 2杜松明,马冠生.儿童肥胖影响因素的研究进展[J].国外医学(卫生学分册),2006,33(5):265-270. 被引量:21
  • 3曾涛.常用减肥药物的不良反应[J].中国药师,2007,10(6):599-601. 被引量:28
  • 4张可.奥利司他干预治疗肥胖并糖耐量减低的疗效观察[J].中原医刊,2007,34(17):74-75. 被引量:4
  • 5Jensen MD,Ryan DH,Apovian CM. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults:A Report of the American College of Cardiology/American Heart As-sociation Task Force on Practice Guidelines and The Obesity Society[J].CIRCULATION,2013.23-27.
  • 6Flegal KM,Carroll MD,Kit BK. Prevalence of obesity and trends in the distribution of body mass index among US adults,1999-2010[J].JAMA:the Journal of the American Medical Association,2012,(05):491-497.
  • 7Finkelstein EA,Trogdon JG,Cohen JW. Annual medical spending attributable to obesity:payer-and service-specific estimates[J].HEALTH AFFAIRS,2009,(05):w822-w831.
  • 8Heisler LK,Jobst EE,Sutton GM. Serotonin reciprocally reg-ulates melanocortin neurons to modulate food intake[J].NEURON,2006,(02):239-249.
  • 9Thomsen WJ,Grottick AJ,Menzaghi F. Lorcaserin,a novel selective human 5-hydroxytryptamine2C agonist:in vitro and in vivo pharmacological characterization[J].Journal of Pharmacology and Experimental Therapeutics,2008,(02):577-587.
  • 10Berger M,Gray JA,Roth BL. The expanded biology of serotonin[J].Annu Re Med,2009.355-366.

引证文献6

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部